Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAbzena Regulatory News (ABZA)

  • There is currently no data for ABZA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Abzena Plc

22 Aug 2018 18:09

RNS Number : 6202Y
Abzena PLC
22 August 2018
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Serrado Healthcare Fund LP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Abzena PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

20 August 2018

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

ORD GBP0.002

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

4,294,456

2.00%

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

4,294,456

2.00%

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

20 August 2018

Contact name:

Stewart Hen, Serrado Healthcare Fund LP

Telephone number*:

1+ (212) 682 1773

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETUUVNRWVAWUAR
Date   Source Headline
17th Aug 201810:17 amRNSForm 8.5 (EPT/RI) Abzena
17th Aug 20188:52 amRNSForm 8.3 - ABZENA PLC
17th Aug 20188:19 amRNSForm 8.5 (EPT/RI) - Abzena Plc
16th Aug 20187:19 amRNSUpdate on partial monetisation
16th Aug 20187:16 amRNSRecommended Cash Offer for Abzena plc
8th Aug 20187:00 amRNSFirst ABZENA Inside GMP drug substance released
6th Jul 20183:55 pmRNSBlocklisting update
2nd Jul 20187:00 amRNSAbzena and Telix sign manufacturing agreement
19th Jun 201812:28 pmRNSAnnual Report and Accounts
14th Jun 20187:00 amRNSFunding update
4th Jun 20187:00 amRNSFinal Results
29th May 20189:00 amRNSNotice of full year results
16th Apr 20187:25 amRNSPre-Close Period Trading Update FY2018
9th Apr 20188:25 amRNSTermination of licence agreement
29th Mar 20185:34 pmRNSIssue of Ordinary Shares
5th Mar 20187:00 amRNSPacificGMP Stanford Settlement
23rd Feb 20187:15 amRNSHardman & Co Research: Investing for growth
5th Jan 20187:00 amRNSBusiness update on US and UK facilities
3rd Jan 20186:12 pmRNSBlock Listing Update
12th Dec 20177:00 amRNSHalf year results: Growth strategy progressing
11th Dec 20177:00 amRNSAbzena secures ADC manufacturing services contract
21st Nov 20179:51 amRNSNotice of half year results
8th Nov 20172:28 pmRNSTR-1: Notification of major holdings
24th Oct 20174:15 pmRNSExercise of options
27th Sep 20177:15 amRNSHardman Research: AGM statement fully discounted
19th Sep 20172:25 pmRNSTR-1: Notification of Major Holdings
19th Sep 20177:00 amRNSAppointment of Non-Executive Director
18th Sep 20175:41 pmRNSTR-1: Notification of Major Holdings
14th Sep 201712:46 pmRNSResult of AGM
14th Sep 20177:00 amRNSTrading Update
31st Aug 201712:15 pmRNSHardman Resrch: Accelerating towards profitability
29th Aug 20172:59 pmRNSTR-1: Notification of major holdings
29th Aug 20177:00 amRNSNotification of claim
21st Aug 20171:44 pmRNSHolding(s) in Company
28th Jul 201712:27 pmRNSNotice of AGM
18th Jul 20177:00 amRNSAbzena and Telix sign licence agreement
11th Jul 20177:00 amRNSAbzena and OBI Pharma sign licence agreement
4th Jul 201711:24 amRNSExercise of Options
3rd Jul 20176:11 pmRNSBlock Listing Update
30th Jun 20175:19 pmRNSTR-1: Notification of Major Interest in Shares
19th Jun 20175:18 pmRNSAnnual Report and Accounts
13th Jun 20177:00 amRNSFinal Results
26th May 20175:24 pmRNSTR-1: Notification of Major Interest in Shares
24th May 20177:11 amRNSAbzena notes True North Therapeutics acquisition
16th May 20177:00 amRNSNotice of Full Year Results
3rd May 201712:58 pmEQSEdison issues outlook on Abzena (ABZA)
3rd May 20177:15 amRNSHardman: Acceleration towards profitability
27th Apr 201711:09 amRNSTR-1: Notification of Major Interest in Shares
21st Apr 201711:21 amRNSInnovations invests £2.9m in Abzena placing
21st Apr 201711:20 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.